HER2 gene amplification or somatic mutation is found in 7% of CRC patients and HER2 positivity is more frequent in patients with KRAS, neuroblastoma RAS viral oncogene homolog (NRAS), or BRAF wt mCRC. Here, KRAS is linked to colorectal carcinoma.